CA2141691C - Formes posologiques solides possedant un profil de liberation prolongee en deux etapes; procede de fabrication - Google Patents
Formes posologiques solides possedant un profil de liberation prolongee en deux etapes; procede de fabrication Download PDFInfo
- Publication number
- CA2141691C CA2141691C CA002141691A CA2141691A CA2141691C CA 2141691 C CA2141691 C CA 2141691C CA 002141691 A CA002141691 A CA 002141691A CA 2141691 A CA2141691 A CA 2141691A CA 2141691 C CA2141691 C CA 2141691C
- Authority
- CA
- Canada
- Prior art keywords
- water
- casein
- salt
- insoluble
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1658—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Botany (AREA)
- Zoology (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4225730A DE4225730C2 (de) | 1992-08-04 | 1992-08-04 | Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung |
DEP4225730.1 | 1992-08-04 | ||
PCT/EP1993/002074 WO1994003158A1 (fr) | 1992-08-04 | 1993-08-04 | Formes galeniques pharmaceutiques solides a profil de liberation prolonge en deux etapes et leur production |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2141691A1 CA2141691A1 (fr) | 1994-02-17 |
CA2141691C true CA2141691C (fr) | 2002-04-09 |
Family
ID=6464804
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002141691A Expired - Lifetime CA2141691C (fr) | 1992-08-04 | 1993-08-04 | Formes posologiques solides possedant un profil de liberation prolongee en deux etapes; procede de fabrication |
Country Status (17)
Country | Link |
---|---|
US (1) | US5382601A (fr) |
EP (1) | EP0582186B1 (fr) |
JP (1) | JP3560244B2 (fr) |
CN (1) | CN1086708A (fr) |
AT (1) | ATE176866T1 (fr) |
AU (1) | AU669731B2 (fr) |
CA (1) | CA2141691C (fr) |
DE (2) | DE4225730C2 (fr) |
DK (1) | DK0582186T3 (fr) |
ES (1) | ES2128369T3 (fr) |
GR (1) | GR3030227T3 (fr) |
IL (1) | IL106580A (fr) |
LT (1) | LT3201B (fr) |
LV (1) | LV10182B (fr) |
MX (1) | MX9304675A (fr) |
WO (1) | WO1994003158A1 (fr) |
ZA (1) | ZA935614B (fr) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5817336A (en) * | 1993-04-02 | 1998-10-06 | Orion-Yhtyma Oy | Composition containing selegiline |
AUPN605795A0 (en) * | 1995-10-19 | 1995-11-09 | F.H. Faulding & Co. Limited | Analgesic pharmaceutical composition |
US6139872A (en) * | 1996-08-14 | 2000-10-31 | Henkel Corporation | Method of producing a vitamin product |
US6057373A (en) * | 1997-05-22 | 2000-05-02 | Synchroneuron, Llc | Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists |
US5866585A (en) * | 1997-05-22 | 1999-02-02 | Synchroneuron, Llc | Methods of treating tardive dyskinesia using NMDA receptor antagonists |
AU3860797A (en) * | 1997-07-16 | 1999-02-10 | Antrin Research Limited | Pharmaceutical formulations for oral administration |
US5840334A (en) * | 1997-08-20 | 1998-11-24 | Fuisz Technologies Ltd. | Self-binding shearform compositions |
US5980941A (en) * | 1997-08-20 | 1999-11-09 | Fuisz Technologies Ltd. | Self-binding shearform compositions |
US6294583B1 (en) | 1998-01-13 | 2001-09-25 | Synchroneuron, Llc | Methods of treating tardive dyskinesia and other movement disorders |
US5952389A (en) * | 1998-01-13 | 1999-09-14 | Synchroneuron | Methods of treating tardive dyskinesia and other movement disorders |
DE19809242A1 (de) * | 1998-03-05 | 1999-09-09 | Basf Ag | Verfahren zur Herstellung von festen, sphärischen Formkörpern, enthaltend pharmazeutische Wirkstoffe in einer Bindemittelmatrix |
DE19814257A1 (de) | 1998-03-31 | 1999-10-07 | Asta Medica Ag | Brauseformulierungen |
US6444702B1 (en) | 2000-02-22 | 2002-09-03 | Neuromolecular, Inc. | Aminoadamantane derivatives as therapeutic agents |
EP1852113A3 (fr) * | 2000-12-07 | 2008-03-12 | Neuromolecular Inc. | Interface d'utilisateur pour contrôler de nombreux paramètres et procédé de contrôle de nombreux paramètres |
US20040122090A1 (en) * | 2001-12-07 | 2004-06-24 | Lipton Stuart A. | Methods for treating neuropsychiatric disorders with nmda receptor antagonists |
KR20060124731A (ko) * | 2004-01-29 | 2006-12-05 | 뉴로몰레큘라 파마슈티칼스, 인코포레이티드 | 중추신경계-관련 질환 치료용 nmda 수용체 길항제 및mao-억제제 또는 gadph-억제제의 배합물 |
US20050209218A1 (en) * | 2004-02-13 | 2005-09-22 | Meyerson Laurence R | Methods and compositions for the treatment of psychiatric conditions |
EP1727538A2 (fr) * | 2004-02-13 | 2006-12-06 | Neuromolecular Inc. | Methodes et compositions destinees au traitement de l'epilepsie, des troubles epileptiques et d'autres troubles du systeme nerveux central |
US20060002999A1 (en) * | 2004-06-17 | 2006-01-05 | Forest Laboratories, Inc. | Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane |
ES2483126T3 (es) * | 2004-06-17 | 2014-08-05 | Merz Pharma Gmbh & Co. Kgaa | Formulaciones de formas de dosificación de neramexano |
JP2008503475A (ja) * | 2004-06-17 | 2008-02-07 | フォーレスト ラボラトリーズ, インコーポレイテッド | メマンチンの放出が改変された製剤 |
KR100901927B1 (ko) * | 2004-06-17 | 2009-06-10 | 메르츠 파마 게엠베하 운트 코. 카가아 | 메만타인 또는 네라멕산의 직접 압축으로 제조된 마실수 있는 즉시 방출형 제제 |
SG157415A1 (en) * | 2004-11-23 | 2009-12-29 | Adamas Pharmaceuticals Inc | Composition comprising a sustained release coating or matrix and an nmda receptor antagonist, method for administration such nmda antagonist to a subject |
US7619007B2 (en) | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
EP1845968A2 (fr) | 2004-11-24 | 2007-10-24 | Neuromolecular Pharmaceuticals, Inc | Composition et methode pour traiter des affections neurologiques |
US20070129402A1 (en) * | 2004-12-27 | 2007-06-07 | Eisai Research Institute | Sustained release formulations |
US20060280789A1 (en) * | 2004-12-27 | 2006-12-14 | Eisai Research Institute | Sustained release formulations |
US20090208579A1 (en) * | 2004-12-27 | 2009-08-20 | Eisai R & D Management Co., Ltd. | Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same |
US20060160852A1 (en) * | 2004-12-27 | 2006-07-20 | Eisai Co. Ltd. | Composition containing anti-dementia drug |
JP2008525313A (ja) * | 2004-12-27 | 2008-07-17 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 抗痴呆薬の安定化方法 |
CA2604052C (fr) * | 2005-04-06 | 2014-07-08 | Adamas Pharmaceuticals, Inc. | Methode et compositions de traitement des affections du snc |
KR101213345B1 (ko) * | 2005-04-28 | 2012-12-17 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 항치매약을 함유하는 조성물 |
WO2006119329A2 (fr) * | 2005-05-02 | 2006-11-09 | Combinatorx, Incorporated | Compositions et procedes pour traiter des maladies neurodegeneratives |
EA013474B1 (ru) * | 2005-06-16 | 2010-04-30 | Форест Лэборэтериз, Инк. | Композиция в виде гранул с модифицированным и немедленным высвобождением мемантина |
WO2007071257A1 (fr) * | 2005-12-23 | 2007-06-28 | Alk-Abelló A/S | Procede d’evaluation de la dissolution de produits pharmaceutiques |
WO2008005534A2 (fr) * | 2006-07-06 | 2008-01-10 | Forest Laboratories, Inc. | Formulations à dissolution orale de mémantine |
US20080069961A1 (en) * | 2006-09-14 | 2008-03-20 | Halliburton Energy Services, Inc. | Methods and compositions for thermally treating a conduit used for hydrocarbon production or transmission to help remove paraffin wax buildup |
GB0623897D0 (en) * | 2006-11-30 | 2007-01-10 | Pliva Istrazivanje I Razvoj D | Pharmaceutical composition of memantine |
US20080182908A1 (en) * | 2007-01-25 | 2008-07-31 | Vinita Umashankar Vyas | Pharmaceutical compositions comprising memantine |
WO2009084017A2 (fr) | 2007-10-10 | 2009-07-09 | Rubicon Research Private Limited | Comprimés de chlorhydrate de mémantine à dissolution orale et au goût masqué |
US20090247644A1 (en) * | 2008-03-28 | 2009-10-01 | Forest Laboratories Holdings Limited | Memantine formulations |
MX2012006320A (es) | 2009-12-02 | 2013-01-18 | Adamas Pharmaceuticals Inc | Composiciones de amantadina y metodos para su uso. |
EP2363119A1 (fr) * | 2010-03-05 | 2011-09-07 | Centre Hospitalier Universitaire d'Angers | Nouvelle composition pharmaceutique utile pour le traitement des personnes affectées par des maladies neurodégénératives ou neurovasculaires |
WO2012101653A2 (fr) | 2011-01-25 | 2012-08-02 | Cadila Healthcare Limited | Compositions pharmaceutiques de mémantine à libération modifiée |
EP2675435A1 (fr) | 2011-02-17 | 2013-12-25 | Lupin Limited | Composition à libération prolongée de mémantine |
TR201104108A2 (tr) | 2011-04-27 | 2011-08-22 | Ali̇ Rai̇f İlaç Sanayi̇ A.Ş. | Uzatılmış salımlı memantin tablet. |
FR2980973B1 (fr) * | 2011-10-11 | 2013-11-15 | Univ Clermont Auvergne | Composition pour le traitement prophylactique de la douleur neuropathique. |
US20130274342A1 (en) * | 2012-04-12 | 2013-10-17 | Cerecor, Inc. | Compositions and methods for treating cough |
IN2015DN01023A (fr) | 2012-08-16 | 2015-06-26 | Teva Pharma | |
CN105121559A (zh) * | 2013-02-08 | 2015-12-02 | 巴斯夫欧洲公司 | 通过反应喷雾干燥的无机/有机复合材料的制备 |
US10154971B2 (en) | 2013-06-17 | 2018-12-18 | Adamas Pharma, Llc | Methods of administering amantadine |
MX2020002078A (es) | 2017-08-24 | 2020-09-21 | Adamas Pharma Llc | Composiciones de amantadina, preparaciones de estas y métodos de uso. |
US20190247331A1 (en) | 2018-02-15 | 2019-08-15 | Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság | Composition and method for treating neurological disease |
US10213394B1 (en) | 2018-02-15 | 2019-02-26 | Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság | Composition and method for treating neurological disease |
US10213393B1 (en) | 2018-02-15 | 2019-02-26 | Osmotica Kereskedelmi és Szolgáltató Korlátolt Feleõsségû Társaság | Composition and method for treating neurological disease |
US11602507B2 (en) | 2019-05-27 | 2023-03-14 | Trikona Pharmaceuticals Pvt. Ltd | Extended release oral composition of memantine or its salt and its process for the preparation |
CU20200087A7 (es) | 2020-11-24 | 2022-07-08 | Centro De Neurociencias De Cuba | Composición farmacéutica de derivados de naftaleno como agentes terapéuticos multiblancos para el tratamiento de la enfermedad de alzheimer |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB715874A (en) * | 1952-10-03 | 1954-09-22 | Horlicks Ltd | A tablet for use in treating peptic ulcers |
GB840091A (en) * | 1955-09-08 | 1960-07-06 | Upjohn Co | Improvements in or relating to therapeutic compositions and the manufacture thereof |
US3594467A (en) * | 1968-10-09 | 1971-07-20 | Richardson Merrell Inc | Long-lasting troche |
ES413944A1 (es) * | 1972-04-20 | 1976-06-01 | Merz & Co | Procedimiento para la preparacion de compuestos de adamen- tano trisustituidos en las posiciones 1,3,5. |
US4076846A (en) * | 1974-11-22 | 1978-02-28 | Sumitomo Bakelite Company Limited | Protein-starch binary molding composition and shaped articles obtained therefor |
US4127650A (en) * | 1975-03-31 | 1978-11-28 | William H. Rorer, Inc. | Medicinal simethicone containing composition and its method of production |
US4419369A (en) * | 1980-09-22 | 1983-12-06 | Baylor College Of Medicine | Protein mineral dietary module |
US4346112A (en) * | 1981-06-29 | 1982-08-24 | University Patents Inc. | Composition and method for treating patients having Parkinson's Disease |
JPS59101423A (ja) * | 1982-12-02 | 1984-06-12 | Takada Seiyaku Kk | 新規なニフエジピン固形製剤 |
US4913906B1 (en) * | 1985-02-28 | 2000-06-06 | Yissum Res Dev Co | Controlled release dosage form of valproic acid |
EP0211294A3 (fr) * | 1985-08-06 | 1988-11-17 | Eltech Systems Corporation | Agent de traitement pour les liquides |
US4897380A (en) * | 1985-08-30 | 1990-01-30 | Pollack Robert L | Method and composition for relieving dietary-related disorders |
US4853377A (en) * | 1985-10-15 | 1989-08-01 | Pollack Robert L | Method and composition for increasing production of serotonin |
DK179687D0 (da) * | 1987-04-08 | 1987-04-08 | Farma Food As | Praeparat |
US4792452A (en) * | 1987-07-28 | 1988-12-20 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
US4925677A (en) * | 1988-08-31 | 1990-05-15 | Theratech, Inc. | Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents |
DE58905637D1 (de) * | 1989-04-14 | 1993-10-21 | Merz & Co Gmbh & Co | Verwendung von Adamantan-Derivaten zur Prävention und Behandlung der cerebralen Ischämie. |
WO1991006287A1 (fr) * | 1989-11-06 | 1991-05-16 | Enzytech, Inc. | Microspheres de proteines et leurs procedes d'utilisation |
GB9004950D0 (en) * | 1990-03-06 | 1990-05-02 | Kelco Int Ltd | Controlled release formulation |
WO1991017745A1 (fr) * | 1990-05-23 | 1991-11-28 | Southwest Research Institute | Systeme a filament d'acheminement d'un medicament et procede |
FR2664499B1 (fr) * | 1990-07-16 | 1994-11-04 | Jacques Dubois | Nouvelles formes pharmaceutiques, leur procede de preparation et leurs applications. |
-
1992
- 1992-08-04 DE DE4225730A patent/DE4225730C2/de not_active Expired - Lifetime
-
1993
- 1993-07-23 US US08/096,952 patent/US5382601A/en not_active Expired - Lifetime
- 1993-07-28 DK DK93112018T patent/DK0582186T3/da active
- 1993-07-28 DE DE59309388T patent/DE59309388D1/de not_active Expired - Lifetime
- 1993-07-28 EP EP93112018A patent/EP0582186B1/fr not_active Expired - Lifetime
- 1993-07-28 ES ES93112018T patent/ES2128369T3/es not_active Expired - Lifetime
- 1993-07-28 AT AT93112018T patent/ATE176866T1/de active
- 1993-08-03 IL IL106580A patent/IL106580A/en not_active IP Right Cessation
- 1993-08-03 ZA ZA935614A patent/ZA935614B/xx unknown
- 1993-08-03 MX MX9304675A patent/MX9304675A/es unknown
- 1993-08-04 CA CA002141691A patent/CA2141691C/fr not_active Expired - Lifetime
- 1993-08-04 LT LTIP839A patent/LT3201B/lt not_active IP Right Cessation
- 1993-08-04 AU AU47069/93A patent/AU669731B2/en not_active Expired
- 1993-08-04 JP JP50501594A patent/JP3560244B2/ja not_active Expired - Fee Related
- 1993-08-04 CN CN93116211A patent/CN1086708A/zh active Pending
- 1993-08-04 LV LVP-93-1013A patent/LV10182B/en unknown
- 1993-08-04 WO PCT/EP1993/002074 patent/WO1994003158A1/fr active Application Filing
-
1999
- 1999-05-14 GR GR990401314T patent/GR3030227T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
LV10182A (lv) | 1994-10-20 |
DE4225730A1 (de) | 1994-02-10 |
ES2128369T3 (es) | 1999-05-16 |
AU669731B2 (en) | 1996-06-20 |
LV10182B (en) | 1995-04-20 |
DE59309388D1 (de) | 1999-04-01 |
DE4225730C2 (de) | 2003-04-30 |
ZA935614B (en) | 1995-02-03 |
AU4706993A (en) | 1994-03-03 |
CA2141691A1 (fr) | 1994-02-17 |
JP3560244B2 (ja) | 2004-09-02 |
EP0582186A1 (fr) | 1994-02-09 |
CN1086708A (zh) | 1994-05-18 |
DK0582186T3 (da) | 1999-09-27 |
EP0582186B1 (fr) | 1999-02-24 |
GR3030227T3 (en) | 1999-08-31 |
IL106580A0 (en) | 1993-12-08 |
JPH07509479A (ja) | 1995-10-19 |
IL106580A (en) | 1998-02-08 |
WO1994003158A1 (fr) | 1994-02-17 |
MX9304675A (es) | 1994-03-31 |
LTIP839A (lt) | 1994-08-25 |
ATE176866T1 (de) | 1999-03-15 |
US5382601A (en) | 1995-01-17 |
LT3201B (en) | 1995-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2141691C (fr) | Formes posologiques solides possedant un profil de liberation prolongee en deux etapes; procede de fabrication | |
EP0338861B1 (fr) | Compositions antiacides à séjour gastrique prolongé | |
EP1058538B1 (fr) | Comprime a desintegration rapide | |
US4708874A (en) | Devices for the controlled release of active substances, as well as process for the preparation thereof | |
PL184407B1 (pl) | Kompozycja farmaceutyczna na granulat mukoadhezyjny i/lub tabletki, zastosowanie granulatu mukoadhezyjnego oraz sposoby wytwarzania granulatu mukoadhezyjnego | |
NZ201008A (en) | Oral preparations containing dipyridamole and at least 5 molar equivalents of orally acceptable acidic excipient | |
SK11062000A3 (sk) | Kompozície obsahujúce celecoxib | |
UA55407C2 (uk) | Тверда нешипуча дозована форма ібупрофену, інгредієнт, який поліпшує здатність її до пресування, та спосіб одержання | |
IE881369L (en) | Cimetidine containing composition | |
CA2212309C (fr) | Formes posologiques orales solides a liberation prolongee de medicaments faiblement solubles dans l'eau | |
US5922351A (en) | Lubricants for use in tabletting | |
IE860433L (en) | Controlled release kcl | |
DK165123B (da) | Fremgangsmaade til mekanisk bearbejdning af cobalt-holdige metaller samt med vand blandbart koncentrat til brug ved fremgangsmaaden | |
US4863743A (en) | Controlled release potassium chloride | |
EP0484106A1 (fr) | Compositions à libération contrôlée | |
JP4719899B2 (ja) | 口腔内速崩壊性錠剤 | |
US5281421A (en) | Gemfibrozil formulations | |
HU196711B (en) | Process for producing long-acting, gastric acid neutralizing pharmaceutics with high acid-binding capacity and increased bioavailability | |
EP0475894A1 (fr) | Formulations améliorées de gemfibozile |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |